加来 啓三

Medicine & Life Sciences

1. Kidney Transplantation 100%
2. Pancreas Transplantation 80%
3. Transplants 74%
4. Living Donors 72%
5. Transplant Recipients 55%
6. Tissue Donors 51%
7. Kidney 42%
8. Tacrolimus 42%
9. Graft Survival 41%
10. Everolimus 37%
11. Cohort Studies 31%
12. Propensity Score 25%
13. Nephrectomy 23%
14. BK Virus 22%
15. Biopsy 20%
16. Pancreas 20%
17. Chronic Kidney Failure 19%
18. Mycophenolic Acid 17%
19. Japan 15%
20. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine 13%
21. Immunosuppression 13%
22. Dialysis 12%
23. MYH9-Related Disorders 12%
24. Observational Studies 12%
25. Allografts 11%
26. Hand 11%
27. Polyomavirus Infections 11%
28. Retrospective Studies 11%
29. Survival Rate 11%
30. Sigmoid Neoplasms 10%
31. Panitumumab 10%
32. Epigastric Arteries 10%
33. Cardiovascular Diseases 10%
34. Polyglycolic Acid 10%
35. Psoas Muscles 10%
36. Fumarates 10%
37. Perforator Flap 9%
38. Thrombelastography 9%
39. Incisional Hernia 9%
40. Transplantation 9%
41. Renal Insufficiency 9%
42. Platelet Transfusion 9%
43. Gastrointestinal Hemorrhage 9%
44. Viral Tumor Antigens 8%
45. Tandem Mass Spectrometry 8%
46. Pancreatectomy 8%
47. Epididymis 8%
48. Diabetic Nephropathies 8%
49. Heart-Assist Devices 8%
50. Therapeutics 8%